The effects of dexmedetomidine dosage on cerebral vasospasm in a rat subarachnoid haemorrhage model

Journal of Clinical Neuroscience

Volumn 17, Issue 6, 2010, Pages 770-773

  Ayoglu, Hilal ^a   Gul, Sanser ^a   Hanci, Volkan ^a   Bahadir, Burak ^a   Bektas, Sibel ^a   Mungan, Ayca Gorkem ^a   Turan, Isil Ozkocak ^a   Acikgoz, Bektas ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Cerebral vasospasm; Dexmedetomidine; Subarachnoid haemorrhage

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CYCLINE; DEXMEDETOMIDINE; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BLOOD VESSEL DIAMETER; BLOOD VESSEL WALL; BRAIN VASOSPASM; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBARACHNOID HEMORRHAGE;

ANALGESICS, NON-NARCOTIC; ANIMALS; DEXMEDETOMIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; PONS; RATS; RATS, WISTAR; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 77953321644     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.10.012     Document Type: Article

References (45)

1. Broderick J.P., Brott T.G., Duldner J.E., et al. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 24 (1994) 1342-1347
2. Ljunggren B., Saveland H., and Brandt L. Causes of unfavorable outcome after early aneurysm operation. Neurosurgery 13 (1983) 629-633
3. Saito I., Asono T., Sano K., et al. Neuroprotective effect of antioxidant, ebselen, in patients with delayed neurological deficits after aneurismal subarachnoid hemorrhage. Neurosurgery 42 (1998) 269-277
4. Kusaka G., Ishikawa M., Nanda A., et al. Signaling pathways for early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab 24 (2004) 916-925
5. Zhou C., Yamaguchi M., Kusaka G., et al. Caspase inhibitors prevent endothelial apoptosis and cerebral vasospasm in dog model of experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab 24 (2004) 419-431
6. Mayberg M.R., Okada T., and Bark D.H. The significance of morphological changes in cerebral arteries after subarachnoid hemorrhage. J Neurosurg 72 (1990) 626-633
7. Ohta T., Satoh G., and Kuroiwa T. The permeability change of major cerebral arteries in experimental vasospasm. Neurosurgery 30 (1992) 331-335
8. Kemaloglu S., Ozkan U., Yilmaz F., et al. Preventive effects of intracisternal alphatocopherol on cerebral vasospasm in experimental subarachnoid hemorrhage. Yonsei Med J 44 (2003) 955-960
9. Kajita Y., Suziki Y., Oyama H., et al. Combined effect of L-arginine and superoxide dismutase on the spastic basilar artery after subarachnoid hemorrhage in dogs. J Neurosurg 80 (1994) 476-483
10. Caner H., Oruckaptan H., Bolay H., et al. The role of lipid peroxidation in the genesis of vasospasm secondary to subarachnoid hemorrhage. Kobe J Med Sci 37 (1991) 13-20
11. Nakagomi T., Kassell N.F., Hongo K., et al. Pharmacological reversibility of experimental cerebral vasospasm. Neurosurgery 27 (1990) 582-586
12. Huang R., Chen Y., Yu A.C., et al. Dexmedetomidine-induced stimulation of glutamine oxidation in astrocytes: a possible mechanism for its neuroprotective activity. J Cereb Blood Flow Metab 20 (2000) 895-898
13. Matsumoto M., Zornow M.H., Rabin B.C., et al. The alpha 2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal norepinephrine concentrations. Brain Res 627 (1993) 325-329
14. Talke P., and Bickler P.E. Effects of dexmedetomidine on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology 85 (1996) 551-557
15. Laudenbach V., Mantz J., Lagercrantz H., et al. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury. Anesthesiology 96 (2002) 134-141
16. Engelhard K., Werner C., Eberspacher E., et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S (+) ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 96 (2003) 524-531
17. Jolkkonen J., Puurrunen K., Koistinaho J., et al. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol 372 (1999) 31-36
18. Wittner M., Sivenius J., and Koistinaho J. Alpha2-adrenoceptor agonist, dexmedetomidine, alters acute gene expression after global ischemia in gerbils. Neurosci Lett 232 (1997) 75-78
19. Ohkawa H., Ohi{dotless}shi{dotless} N., and Yagi{dotless} K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95 (1979) 351-358
20. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
21. Naredi S., Lambert G., and Eden E. Increased sympathetic nervous activity in patients with nontraumatic subarachnoid hemorrhage. Stroke 31 (2000) 901-906
22. Rothoerl R.D., and Ringel F. Molecular mechanisms of cerebral vasospasm following aneurysmal SAH. Neurol Res 29 (2007) 636-642
23. Liu S., Tang J., Ostrowski R.P., et al. Oxidative stress after subarachnoid hemorrhage in gp91phox knockout mice. Can J Neurol Sci 34 (2007) 356-361
24. Songur A., Sarsilmaz M., Sogut S., et al. Hypothalamic superoxide dismutase, xanthine oxidase, nitric oxide, and malondialdehyde in rats fed with fish omega-3 fatty acids. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 693-698
25. Cosar M., Eser O., Fidan H., et al. The neuroprotective effect of dexmedetomidine in the hippocampus of rabbits after subarachnoid hemorrhage. Surg Neurol 71 (2009) 54-59
26. Halonen T., Kotti T., Tuunanen J., et al. Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against, kainic acid-induced convulsions and neuronal damage. Brain Res 693 (1995) 217-224
27. Kuhmonen J., Pokorny J., Miettinen R., et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 87 (1997) 371-377
28. Nishihashi T., Trandafir C.C., Wang A., et al. Hypersensitivity to hydroxyl radicals in rat basilar artery after subarachnoid hemorrhage. J Pharmacol Sci 100 (2006) 234-236
29. Lobato R.D., Marin J., and Salaices M. Cerebrovascular reactivity to noradrenaline and serotonin following experimental subarachnoid hemorrhage. J Neurosurg 53 (1980) 480-485
30. Bromont C., Marie C., and Bralet J. Increased lipid peroxidation in vulnerable brain regions after transient forebrain ischemia in rats. Stroke 20 (1989) 918-924
31. Oliver C.N., Starke-Reed P.E., Stadtman E.R., et al. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl Acad Sci USA 87 (1990) 5144-5157
32. Veyrac A., Didier A., Colpaert F., et al. Activation of noradrenergic transmission by alpha2-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb. Exp Neurol 194 (2005) 444-456
33. Hunter J.C., Fontana D.J., Hedley L.R., et al. Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative, and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 122 (1997) 1339-1344
34. Lakhlani P.P., MacMillan L.B., Guo T.Z., et al. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA 94 (1997) 9950-9955
35. Ma D., Hossain M., Rajakumaraswamy N., et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 502 (2004) 87-97
36. Kader A., Krauss W.E., Onesti S.T., et al. Chronic cerebral blood flow changes following experimental subarachnoid hemorrhage in rats. Stroke 21 (1990) 577-581
37. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
38. Mackness B., Durrington P.N., and Mackness M.I. Human serum paraoxonase. Gen Pharmacol 31 (1998) 329-336
39. Williams F.M., Mutch E., and Blain P.G. Paraoxonase distribution in Caucasian males. Chem Biol Interact 87 (1993) 155-160
40. Mackness M.I., Mackness B., Durrington P.N., et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7 (1996) 69-76
41. Timchalk C., and Poet T.S. Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat. Neurotoxicology 29 (2008) 428-443
42. Mackness M.I., Harty B., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
43. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 473-480
44. Mackness M.I., Mackness B., and Durrington P.N. Paraoxonase and coronary heart disease. Atheroscler Suppl 3 (2002) 49-55
45. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease?. Mol Med Today 5 (1999) 381-386